Genmab — August 2015
-
Arzerra continues to face intense competition and given the competitive
market, we have reduced our estimate of Arzerra royalties to DKK 100 million from our previous estimate
of DKK 125 million. -
Arzerra continues to face intense competition and given the competitive
market, we have reduced our estimate of Arzerra royalties to DKK 100 million from our previous estimate
of DKK 125 million. -
June: An expanded access program for daratumumab was opened for eligible patients in the
U.S. by Janssen. -
de har til 2030 i USA
-
August: Entered a research collaboration for the DuoBody platform with Pierre Fabre.
-
Den var ny
-
De har oveni investeret 113 mio. i intangible assets
-
Jan van der Winkel er i Børsen Play kl. 8,30 i morgen. Derefter i Millionærklubben kl. 9-10. På PI er han på i Q&A kl.15.
-
Husk endeligt at få sendt de skarpe spørgsmål til ham.
-
Nyt Dara studie phase 1 subcutan behandling. https://clinicaltrials.gov/ct2/show/NCT02519452?term=daratumumab&rank=5&submit_fld_opt=
-
Holder analytikerne ferie?
-
Hverken Bowers, Welford eller Parks var med i dag
-
Husk at få smidt Q&A spørgsmål
-
Ved du hvad IV .. jeg tror folk er ved at være lidt metal trætte .. Efterhånden så er det fuldstændig ligegyldgt hvordan Genmab performer .. så sidder der et aktiebanditter og styrer kursen efter godt befindende og jeg er så fucking træt af det .. før i tiden glædede man sig når der kom gode news og så frem til næste dags aktie åbning.. Nu er det rent lotto om der åbnes grønt eller rødt..
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind